drugset
drugset / Trial / NCT05268016

Efficacy and Safety of ME3183 in Subjects With Moderate to Severe Plaque Psoriasis

NCT05268016 ↗

Phase 2 Completed 132 enrolled Meiji Pharma USA Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the efficacy and safety of ME3183 administered orally for moderate to severe plaque psoriasis in adults.

Timeline

Start
2022-03-24
Primary completion
2023-05-31
Completion
2023-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject ME3183 Unknown — Oral

Indications

psoriasis